Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity.~* Subject meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.~* Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45 kg/m2.~* Subject has a Screening serum urate level ≥ 8 mg/dL.~* Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.~Exclusion Criteria:~* Subject is unable to take colchicine for gout flare prophylaxis.~* Subject has a history or suspicion of kidney stones.~* Subject has any gastrointestinal disorder that affects motility and/or absorption.~* Subject had unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.~* Subject has Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.~* Subject has an estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.~* Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.~* Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 2.5 mg, 7.5 mg and 15 mg (Type: EXPERIMENTAL): RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
- RDEA3170 5 mg, 10 mg and 20 mg (Type: EXPERIMENTAL): RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)

Based on this trial design, predict the completion outcome and termination type (if applicable).